Literature DB >> 25139075

Potential association between the recent increase in campylobacteriosis incidence in the Netherlands and proton-pump inhibitor use - an ecological study.

M Bouwknegt1, W van Pelt, M E Kubbinga, M Weda, A H Havelaar.   

Abstract

The Netherlands saw an unexplained increase in campylobacteriosis incidence between 2003 and 2011, following a period of continuous decrease. We conducted an ecological study and found a statistical association between campylobacteriosis incidence and the annual number of prescriptions for proton pump inhibitors (PPIs), controlling for the patient's age, fresh and frozen chicken purchases (with or without correction for campylobacter prevalence in fresh poultry meat). The effect of PPIs was larger in the young than in the elderly. However, the counterfactual population-attributable fraction for PPIs was largest for the elderly (ca 45% in 2011) and increased at population level from 8% in 2004 to 27% in 2011. Using the regression model and updated covariate values, we predicted a trend break for 2012, largely due to a decreased number of PPI prescriptions, that was subsequently confirmed by surveillance data. Although causality was not shown, the biological mechanism, age effect and trend-break prediction suggest a substantial impact of PPI use on campylobacteriosis incidence in the Netherlands. We chose the ecological study design to pilot whether it is worthwhile to further pursue the effect of PPI on campylobacteriosis and other gastrointestinal pathogens in prospective cohort studies. We now provide strong arguments to do so.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25139075     DOI: 10.2807/1560-7917.es2014.19.32.20873

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  14 in total

Review 1.  The influence of proton pump inhibitors and other commonly used medication on the gut microbiota.

Authors:  Floris Imhann; Arnau Vich Vila; Marc Jan Bonder; Ailine G Lopez Manosalva; Debby P Y Koonen; Jingyuan Fu; Cisca Wijmenga; Alexandra Zhernakova; Rinse K Weersma
Journal:  Gut Microbes       Date:  2017-01-24

Review 2.  Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

Authors:  Leon Fisher; Alexander Fisher
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

3.  Risk factors for campylobacteriosis in Australia: outcomes of a 2018-2019 case-control study.

Authors:  Danielle M Cribb; Liana Varrone; Rhiannon L Wallace; Angus T McLure; James J Smith; Russell J Stafford; Dieter M Bulach; Linda A Selvey; Simon M Firestone; Nigel P French; Mary Valcanis; Emily J Fearnley; Timothy S Sloan-Gardner; Trudy Graham; Kathryn Glass; Martyn D Kirk
Journal:  BMC Infect Dis       Date:  2022-06-30       Impact factor: 3.667

4.  Nonlinear machine learning pattern recognition and bacteria-metabolite multilayer network analysis of perturbed gastric microbiome.

Authors:  Claudio Durán; Sara Ciucci; Alessandra Palladini; Umer Z Ijaz; Antonio G Zippo; Francesco Paroni Sterbini; Luca Masucci; Giovanni Cammarota; Gianluca Ianiro; Pirjo Spuul; Michael Schroeder; Stephan W Grill; Bryony N Parsons; D Mark Pritchard; Brunella Posteraro; Maurizio Sanguinetti; Giovanni Gasbarrini; Antonio Gasbarrini; Carlo Vittorio Cannistraci
Journal:  Nat Commun       Date:  2021-03-26       Impact factor: 14.919

5.  Proton pump inhibitors and gastroenteritis.

Authors:  Robert-Jan Hassing; Annelies Verbon; Herman de Visser; Albert Hofman; Bruno H Stricker
Journal:  Eur J Epidemiol       Date:  2016-03-10       Impact factor: 8.082

6.  Public health relevance of drug-nutrition interactions.

Authors:  Szabolcs Péter; Gerjan Navis; Martin H de Borst; Clemens von Schacky; Anne Claire B van Orten-Luiten; Alexandra Zhernakova; Renger F Witkamp; André Janse; Peter Weber; Stephan J L Bakker; Manfred Eggersdorfer
Journal:  Eur J Nutr       Date:  2017-08       Impact factor: 5.614

7.  A combined case-control and molecular source attribution study of human Campylobacter infections in Germany, 2011-2014.

Authors:  Bettina M Rosner; Anika Schielke; Xavier Didelot; Friederike Kops; Janina Breidenbach; Niklas Willrich; Greta Gölz; Thomas Alter; Kerstin Stingl; Christine Josenhans; Sebastian Suerbaum; Klaus Stark
Journal:  Sci Rep       Date:  2017-07-11       Impact factor: 4.379

8.  Cost Effectiveness of Gastroprotection with Proton Pump Inhibitors in Older Low-Dose Acetylsalicylic Acid Users in the Netherlands.

Authors:  Sek Hung Chau; Reinier L Sluiter; Wietske Kievit; Michel Wensing; Martina Teichert; Jacqueline G Hugtenburg
Journal:  Drugs Aging       Date:  2017-05       Impact factor: 3.923

9.  Acid-suppression medications and bacterial gastroenteritis: a population-based cohort study.

Authors:  Li Wei; Lasantha Ratnayake; Gabby Phillips; Chris C McGuigan; Steve V Morant; Robert W Flynn; Isla S Mackenzie; Thomas M MacDonald
Journal:  Br J Clin Pharmacol       Date:  2017-01-23       Impact factor: 4.335

10.  Proton pump inhibitors affect the gut microbiome.

Authors:  Floris Imhann; Marc Jan Bonder; Arnau Vich Vila; Jingyuan Fu; Zlatan Mujagic; Lisa Vork; Ettje F Tigchelaar; Soesma A Jankipersadsing; Maria Carmen Cenit; Hermie J M Harmsen; Gerard Dijkstra; Lude Franke; Ramnik J Xavier; Daisy Jonkers; Cisca Wijmenga; Rinse K Weersma; Alexandra Zhernakova
Journal:  Gut       Date:  2015-12-09       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.